HELIXGEN (Guangzhou) Co., Ltd., located in Guangzhou Science City, was founded in 2008 jointly by a team of biologists, biomedical engineers, entrepreneurs and investors. As a research and development oriented biotechnology company, our focus is on development, manufacturing and sales of IVD products, and providing related technical services as well. With molecular diagnostics and point-of-care testing platforms as our core technology strength, we devote ourselves to the progress of precision medicine.
The HemoPOC® coagulometer, coupled with disposable PT-INR test strips, yields immediate results for the quantitative testing of prothrombin time, allowing patients undergoing oral anticoagulation therapy with Warfarin to monitor their Intemnational Normalized Ratio(INR) using a finger-prick blood test at the point of care.
Based on our cutting edge molecular diagnostic platforms and real-time PCR melting curve analysis technology, HelixGen has successfully developed a series of IVD test kits for personalized medicine applications. These products detect the patient's pharmacokinetics related genotyping, which may assist doctors to determine an appropriate drug dosage for each individual patient, making the treatment safer, more effective and with less side effects.
Partnered with the world's leading technology team, HelixGen has recently launched HelixGenTM MHC Tetramer that can be used for immunology research, immunotherapy and vaccine development. Being able to conjugate with antigen-specific T-cell with high sensitivity and specificity, HelixGenTM MHC Tetramer is perfect for analysis of T-cells, both qualitatively and quantitatively, thus, of great advantage in T-cell sorting, CTL epitope screening, TCR affinity analysis, TCR-like antibody preparation and CAR-T cell studies.
